EP2869821A4 - Compositions et méthodes de traitement et d'inhibition d'infections virales - Google Patents

Compositions et méthodes de traitement et d'inhibition d'infections virales

Info

Publication number
EP2869821A4
EP2869821A4 EP13813787.2A EP13813787A EP2869821A4 EP 2869821 A4 EP2869821 A4 EP 2869821A4 EP 13813787 A EP13813787 A EP 13813787A EP 2869821 A4 EP2869821 A4 EP 2869821A4
Authority
EP
European Patent Office
Prior art keywords
compositions
treating
methods
viral infections
inhibiting viral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP13813787.2A
Other languages
German (de)
English (en)
Other versions
EP2869821A2 (fr
Inventor
Justice E Obi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GRACELAND BIOTECHNOLOGY CATALYST, LLC
Original Assignee
GRACELAND BIOTECHNOLOGY Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/540,749 external-priority patent/US20140011837A1/en
Priority claimed from US13/687,273 external-priority patent/US20140011838A1/en
Priority claimed from US13/932,445 external-priority patent/US20140011839A1/en
Application filed by GRACELAND BIOTECHNOLOGY Inc filed Critical GRACELAND BIOTECHNOLOGY Inc
Publication of EP2869821A2 publication Critical patent/EP2869821A2/fr
Publication of EP2869821A4 publication Critical patent/EP2869821A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP13813787.2A 2012-07-03 2013-07-02 Compositions et méthodes de traitement et d'inhibition d'infections virales Withdrawn EP2869821A4 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US13/540,749 US20140011837A1 (en) 2012-07-03 2012-07-03 Compositions and methods for treating warts associated with viral infections
US13/687,273 US20140011838A1 (en) 2012-07-03 2012-11-28 Compositions and methods for treating warts associated with viral infections
US13/932,445 US20140011839A1 (en) 2012-07-03 2013-07-01 Compositions and methods for treating and inhibiting viral infections
PCT/US2013/049046 WO2014008248A2 (fr) 2012-07-03 2013-07-02 Compositions et méthodes de traitement et d'inhibition d'infections virales

Publications (2)

Publication Number Publication Date
EP2869821A2 EP2869821A2 (fr) 2015-05-13
EP2869821A4 true EP2869821A4 (fr) 2016-04-06

Family

ID=49882589

Family Applications (1)

Application Number Title Priority Date Filing Date
EP13813787.2A Withdrawn EP2869821A4 (fr) 2012-07-03 2013-07-02 Compositions et méthodes de traitement et d'inhibition d'infections virales

Country Status (4)

Country Link
EP (1) EP2869821A4 (fr)
CN (1) CN104703601A (fr)
CA (1) CA2927146A1 (fr)
WO (1) WO2014008248A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2544153B1 (es) 2014-02-24 2016-06-06 Ntd Labs, S.L. Uso de un hidrolizado de caseína como agente antiviral
CN104352495A (zh) * 2014-11-15 2015-02-18 广州凯普生物科技有限公司 一种治疗疣类疾病的药物
JP7176767B2 (ja) * 2017-04-13 2022-11-22 国立大学法人 鹿児島大学 新規なアモジアキン類似体およびその使用方法
US11116808B2 (en) 2018-08-06 2021-09-14 Nielsen Biosciences, Inc. Treatment of warts
CN109288816B (zh) * 2018-12-04 2019-11-22 广州凯普医药科技有限公司 一种氯喹凝胶及其制备方法和应用
CN110917196B (zh) * 2020-02-05 2020-06-05 广州康健医学科技有限公司 一种氯喹抑菌消毒液及其应用
CN112089841A (zh) * 2020-04-05 2020-12-18 徐静 用于治疗上皮组织病毒感染所致疾病的药物组合物
EP4135673A4 (fr) * 2020-04-14 2024-05-08 Glanis Pharmaceuticals, Inc. Système d'administration transdermique et/ou topique comprenant de l'hydroxychloroquine et/ou de la chloroquine
CN114848642A (zh) * 2022-07-07 2022-08-05 广州康健医学科技有限公司 磷酸氯喹在制备防治高危型hpv感染及宫颈癌前病变与宫颈癌的药物中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999052515A2 (fr) * 1998-04-14 1999-10-21 Hassan Jomaa Utilisation de liaisons organophosphorees dans le traitement et la prevention d'infections
EP2581081A3 (fr) * 2007-06-01 2013-07-31 The Trustees Of Princeton University Traitement d'infections virales par modulation de voies métaboliques de cellules hôtes

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JACOBS P H ET AL: "Effect of chloroquine anb placebo on warts", ARCHIVES OF DERMATOLOGY, AMERICAN MEDICAL ASSOCIATION, US, vol. 87, no. 1, 1 January 1963 (1963-01-01), pages 89 - 90, XP009188564, ISSN: 0003-987X *
MURPHY J C ET AL: "Chloroquine treatment of warts. A double-blind clinical study", ROCKY MOUNTAIN MEDICAL JOURNAL, COLORADO MEDICAL SOCIETY, DENVER, CO, US, vol. 62, no. 1, 1 January 1965 (1965-01-01), pages 25 - 26, XP009188565, ISSN: 0035-760X *
ZABEL H ET AL: "Sensitization to light during chloroquine diphosphate therapy", ZEITSCHRIFT FUER HAUT UND GESCHLECHTSKRANKHEITEN, GROSSE, BERLIN, DE, vol. 29, no. 7, 1 January 1960 (1960-01-01), pages 203 - 206, XP009188566, ISSN: 0044-2844 *

Also Published As

Publication number Publication date
WO2014008248A2 (fr) 2014-01-09
CN104703601A (zh) 2015-06-10
EP2869821A2 (fr) 2015-05-13
CA2927146A1 (fr) 2014-01-09
WO2014008248A3 (fr) 2014-02-27

Similar Documents

Publication Publication Date Title
IL277196B (en) Methods and preparations for genome engineering
IL238416A0 (en) Preparations and methods for the treatment of diseases caused by protein pathology
AP3269A (en) Methods and compounds for treating paramyxoviridaevirus infections
LT2925888T (lt) Vėžio gydymo kompozicijos ir būdai
ZA201500921B (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diaseases
SG11201507507PA (en) Compositions and methods for treating mpsi
DK3292875T3 (en) Compositions and methods for treating diseases
SG11201402609RA (en) Compositions and methods for treating hepatitis c virus
EP2817018A4 (fr) Procédés et compositions pour empêcher ou traiter les conditions ophtalmiques
IL237173B (en) Methods for treating hepatitis b and hepatitis d infections
IL234829A0 (en) Methods and preparations for treating inflammation
EP2869821A4 (fr) Compositions et méthodes de traitement et d'inhibition d'infections virales
IL233968A (en) Compounds and preparations containing them for the treatment of fibrosis
ZA201503474B (en) Compositions and methods for treating bacterial infections
EP2624841A4 (fr) Compositions pour traitement d'infections virales chroniques
ZA201501601B (en) Virus purification and formulation process
IL238403A0 (en) Methods and preparations for the treatment of progesterone-dependent conditions
PL2838903T3 (pl) Sposoby i kompozycje do leczenia zakażeń wirusowych
EP2887967A4 (fr) Compositions et méthodes de traitement d'un cancer hépatocellulaire
EP2838526A4 (fr) Matériaux et méthodes utilisés pour prévenir et traiter des infections virales
ZA201308683B (en) Methods and compositions suitable for preventing and treating hyperleptinemia
SG11201402899TA (en) Methods and compositions for treating viral diseases
GB201222736D0 (en) Composition and process
AU2012905097A0 (en) Agents and methods for inhibiting virus infection
EP2747765A4 (fr) Compositions et procédés destinés au traitement de maladies virales

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20150127

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20160304

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 31/20 20060101ALI20160229BHEP

Ipc: A61K 31/4706 20060101AFI20160229BHEP

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: GRACELAND BIOTECHNOLOGY CATALYST, LLC

Owner name: OBI, JUSTICE E.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20180201